Literature DB >> 35213158

Discovery of Anticancer Agents of Diverse Natural Origin.

Leslie N Aldrich1, Joanna E Burdette2, Esperanza Carcache de Blanco3, Christopher C Coss3, Alessandra S Eustaquio2, James R Fuchs3, A Douglas Kinghorn3, Amanda MacFarlane4, Brittney K Mize3, Nicholas H Oberlies5, Jimmy Orjala2, Cedric J Pearce6, Mitch A Phelps3, Liva Harinantenaina Rakotondraibe3, Yulin Ren3, Djaja Doel Soejarto2,7, Brent R Stockwell, Jack C Yalowich3, Xiaoli Zhang8.   

Abstract

Research progress from mainly over the last five years is described for a multidisciplinary collaborative program project directed toward the discovery of potential anticancer agents from a broad range of taxonomically defined organisms. Selected lead compounds with potential as new antitumor agents that are representative of considerable structural diversity have continued to be obtained from each of tropical plants, terrestrial and aquatic cyanobacteria, and filamentous fungi. Recently, a new focus has been on the investigation of the constituents of U.S. lichens and their fungal mycobionts. A medicinal chemistry and pharmacokinetics component of the project has optimized structurally selected lead natural products, leading to enhanced cytotoxic potencies against selected cancer cell lines. Biological testing has shown several compounds to have in vivo activity, and relevant preliminary structure-activity relationship and mechanism of action studies have been performed. Several promising lead compounds worthy of further investigation have been identified from the most recent collaborative work performed.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35213158      PMCID: PMC9034850          DOI: 10.1021/acs.jnatprod.2c00036

Source DB:  PubMed          Journal:  J Nat Prod        ISSN: 0163-3864            Impact factor:   4.803


  119 in total

Review 1.  Biological targets and mechanisms of action of natural products from marine cyanobacteria.

Authors:  Lilibeth A Salvador-Reyes; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2015-03       Impact factor: 13.423

2.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

3.  Previously Uncharacterized Vacuolar-type ATPase Binding Site Discovered from Structurally Similar Compounds with Distinct Mechanisms of Action.

Authors:  Andrew C Wang; Helen T Pham; Jennifer M Lipps; Scott M Brittain; Edmund Harrington; Yuan Wang; Fred J King; Carsten Russ; Xuewen Pan; Dominic Hoepfner; John Tallarico; Yan Feng; Rishi K Jain; Markus Schirle; Jason R Thomas
Journal:  ACS Chem Biol       Date:  2018-12-18       Impact factor: 5.100

4.  ZT-25, a new vacuolar H(+)-ATPase inhibitor, induces apoptosis and protective autophagy through ROS generation in HepG2 cells.

Authors:  Yapeng Lu; Rui Zhang; Siyuan Liu; Yu Zhao; Jing Gao; Li Zhu
Journal:  Eur J Pharmacol       Date:  2015-12-12       Impact factor: 4.432

5.  Cylindrocyclophane biosynthesis involves functionalization of an unactivated carbon center.

Authors:  Hitomi Nakamura; Hilary A Hamer; Gopal Sirasani; Emily P Balskus
Journal:  J Am Chem Soc       Date:  2012-11-02       Impact factor: 15.419

6.  Verticillin A Causes Apoptosis and Reduces Tumor Burden in High-Grade Serous Ovarian Cancer by Inducing DNA Damage.

Authors:  Amrita Salvi; Chiraz Soumia M Amrine; Julia R Austin; KiAundra Kilpatrick; Angela Russo; Daniel Lantvit; Esther Calderon-Gierszal; Zachary Mattes; Cedric J Pearce; Mark W Grinstaff; Aaron H Colby; Nicholas H Oberlies; Joanna E Burdette
Journal:  Mol Cancer Ther       Date:  2020-01       Impact factor: 6.261

7.  Semisynthetic Derivatives of the Verticillin Class of Natural Products through Acylation of the C11 Hydroxy Group.

Authors:  Chiraz Soumia M Amrine; Andrew C Huntsman; Michael G Doyle; Joanna E Burdette; Cedric J Pearce; James R Fuchs; Nicholas H Oberlies
Journal:  ACS Med Chem Lett       Date:  2021-03-19       Impact factor: 4.345

8.  FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.

Authors:  Sonia Singh; Adnan A Jaigirdar; Flora Mulkey; Joyce Cheng; Salaheldin S Hamed; Yangbing Li; Jiang Liu; Hong Zhao; Anwar Goheer; Whitney S Helms; Xing Wang; Rajiv Agarwal; Rajan Pragani; Kwadwo Korsah; Shenghui Tang; John Leighton; Atiqur Rahman; Julia A Beaver; Richard Pazdur; Marc R Theoret; Harpreet Singh
Journal:  Clin Cancer Res       Date:  2020-12-07       Impact factor: 13.801

9.  Greensporones: resorcylic acid lactones from an aquatic Halenospora sp.

Authors:  Tamam El-Elimat; Huzefa A Raja; Cynthia S Day; Wei-Lun Chen; Steven M Swanson; Nicholas H Oberlies
Journal:  J Nat Prod       Date:  2014-08-05       Impact factor: 4.050

10.  Assembly line termination in cylindrocyclophane biosynthesis: discovery of an editing type II thioesterase domain in a type I polyketide synthase.

Authors:  H Nakamura; J X Wang; E P Balskus
Journal:  Chem Sci       Date:  2015-04-14       Impact factor: 9.825

View more
  2 in total

1.  Molecular-docking-guided design, palladium-catalyzed synthesis and anticancer activity of paclitaxel-benzoxazoles hybrids.

Authors:  Ting Jiang; Ya-Nan Cao; Jin-Bu Xu; Feng Gao; Ling-Li Zheng
Journal:  Sci Rep       Date:  2022-06-15       Impact factor: 4.996

Review 2.  Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides.

Authors:  Søren Brøgger Christensen
Journal:  Molecules       Date:  2022-09-01       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.